Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.  

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.

Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well tolerated and generates potent and long-lasting neoantigen-specific T cell responses Updated data to be presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

InSphero, the pioneer in 3D cell culture and organ-on-chip technologies, today announced its distribution partnership with Chayon, a leading Seoul-based laboratory supplies provider. This partnership will bring InSphero’s reliable and scalable 3D in vitro solutions for drug development to South Korean researchers, further expanding the company’s global footprint.

LubioScience GmbH, Switzerland’s leading life science distributor, has partnered with Zymo Research to bring specialized Next-Generation Sequencing (NGS) services for epigenetics and microbiomics to the Swiss market. This collaboration enables Swiss biotech companies to obtain reliable NGS data with faster turnaround times and highly competitive pricing.